John George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John George has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Tareq Alsaleh
Internal Medicine, AdventHealth Orlando
3 shared publications- Mohamad Khaled Almujarkesh
Center for Interventional Endoscopy, AdventHealth, Orlando, FL
2 shared publications - Tareq Alsaleh
Internal Medicine, AdventHealth Orlando, Orlando, FL, USA
2 shared publications - Abdullah Abbasi
Center for Interventional Endoscopy (CIE), AdventHealth Orlando, Orlando, FL
1 shared publication Aleena Majeed
Internal Medicine, AdventHealth Orlando
1 shared publication- Babu Pappu Mohan
University of Central Florida School of Medicine, Orlando, FL
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1954055
Placebo-arm response rates for pain outcomes in chronic pancreatitis: a systematic review and meta-analysis of randomized controlled trials
Background: Improvement in the placebo arm can influence chronic pancreatitis (CP) pain trials, yet contemporary estimates of placebo-arm response are limited. We aimed to quantify placebo-arm pain response rates in medical placebo-controlled randomized controlled trials (RCTs) of CP-related abdominal pain. Methods: PubMed, Web of Science, Embase, and Scopus were searched from inception to October 2025 for placebo-controlled RCTs reporting pain response among placebo-treated patients with CP. Crossover trials, procedural or device-based sham-controlled trials, and studies without extractable placebo-arm pain-response data were excluded. The primary outcome was the pooled proportion of placebo-treated patients achieving pain response according to study-specific definitions. Random-effects meta-analysis of single proportions was performed. Subgroup analyses categorized endpoints as partial pain improvement or complete pain resolution. Risk of bias was assessed using Cochrane RoB 2. Results: Seven RCTs including 321 placebo-treated patients, 320 of whom contributed pain-response data, met inclusion criteria. Follow-up ranged from 3 to 26 weeks. One study was judged low risk of bias and six had some concerns; no study was high risk. The pooled placebo-arm pain response rate was 26% (95% CI, 17%–36%), with heterogeneity (I² = 74.8%). Response rates varied with endpoint stringency, although the difference between subgroups was not statistically significant (P = 0.18): 31% (95% CI, 18%–46%; I² = 73.7%) in trials using partial pain improvement criteria and 20% (95% CI, 12%–29%; I² = 42.1%) in trials requiring complete pain resolution. Leave-one-out sensitivity analysis did not materially alter the estimate. Conclusions: One-quarter of placebo-treated patients in CP RCTs experience pain response. Endpoint stringency may influence observed placebo-arm response and should be considered in sample-size estimation, outcome selection, and interpretation of CP pain trials.
- 22 October 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1954055
Open AccessPlacebo-arm response rates for pain outcomes in chronic pancreatitis: a systematic review and meta-analysis of randomized controlled trials
Background: Improvement in the placebo arm can influence chronic pancreatitis (CP) pain trials, yet contemporary estimates of placebo-arm response are limited. We aimed to quantify placebo-arm pain response rates in medical placebo-controlled randomized controlled trials (RCTs) of CP-related abdominal pain. Methods: PubMed, Web of Science, Embase, and Scopus were searched from inception to October 2025 for placebo-controlled RCTs reporting pain response among placebo-treated patients with CP. Crossover trials, procedural or device-based sham-controlled trials, and studies without extractable placebo-arm pain-response data were excluded. The primary outcome was the pooled proportion of placebo-treated patients achieving pain response according to study-specific definitions. Random-effects meta-analysis of single proportions was performed. Subgroup analyses categorized endpoints as partial pain improvement or complete pain resolution. Risk of bias was assessed using Cochrane RoB 2. Results: Seven RCTs including 321 placebo-treated patients, 320 of whom contributed pain-response data, met inclusion criteria. Follow-up ranged from 3 to 26 weeks. One study was judged low risk of bias and six had some concerns; no study was high risk. The pooled placebo-arm pain response rate was 26% (95% CI, 17%–36%), with heterogeneity (I² = 74.8%). Response rates varied with endpoint stringency, although the difference between subgroups was not statistically significant (P = 0.18): 31% (95% CI, 18%–46%; I² = 73.7%) in trials using partial pain improvement criteria and 20% (95% CI, 12%–29%; I² = 42.1%) in trials requiring complete pain resolution. Leave-one-out sensitivity analysis did not materially alter the estimate. Conclusions: One-quarter of placebo-treated patients in CP RCTs experience pain response. Endpoint stringency may influence observed placebo-arm response and should be considered in sample-size estimation, outcome selection, and interpretation of CP pain trials.
- Open Access
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1857141
Pharmacological and non-pharmacological therapies for chronic pancreatitis pain: a narrative review
Importance: Chronic pancreatitis (CP) pain is the major driver of morbidity, reduced quality of life, healthcare use, and opioid exposure in affected patients. Pain in CP is heterogeneous and often correlates poorly with structural pancreatic abnormalities alone. It may arise from overlapping obstructive, neuropathic, nociplastic, and psychosocial mechanisms, making simple stepwise analgesic escalation insufficient for many patients. Observations: The emerging evidence supports a multidimensional strategy for treating CP pain. In some patients, pain is driven mainly by ductal obstruction, stones, strictures, inflammatory head masses, or other structural complications that may respond to endoscopic or surgical decompression. On the other hand, pain may persist because of pancreatic neuroplasticity, peripheral nerve injury, central sensitization, widespread hyperalgesia, and psychological distress. Newer tools such as the Comprehensive Pain Assessment Tool Short Form, electronic body mapping, and pancreatic quantitative sensory testing may help identify clinically relevant pain phenotypes beyond imaging alone. Although pharmacologic options remain limited, medications can provide relief in appropriately selected patients. Pregabalin has the strongest direct evidence among neuromodulators with favorable results. However, opioids remain widely prescribed even though they worsen dependency, opioid-induced hyperalgesia, and treatment resistance when used without reassessment of the dominant pain mechanism. Nonpharmacological modalities are an essential component. These include alcohol and smoking cessation, nutritional and endocrine optimization, and cognitive behavioral therapy. Endoscopic and surgical therapies are most effective when pain is anatomy-driven, while neuromodulation and other emerging interventions remain investigational but may be a promising option for nociplastic pain. Conclusions and relevance: Pain in CP should be approached as a dynamic biopsychosocial process by a multidisciplinary team. In addition to pain intensity, outcome measures should capture pain interference, function, quality of life, and opioid burden. Correctly identifying the pain phenotype and matching patients with the appropriate mechanism-based therapies and structural interventions will maximize treatment success and reduce prolonged opioid escalation and repeated low-yield interventions.
- 22 June 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1857141
Open AccessPharmacological and non-pharmacological therapies for chronic pancreatitis pain: a narrative review
Importance: Chronic pancreatitis (CP) pain is the major driver of morbidity, reduced quality of life, healthcare use, and opioid exposure in affected patients. Pain in CP is heterogeneous and often correlates poorly with structural pancreatic abnormalities alone. It may arise from overlapping obstructive, neuropathic, nociplastic, and psychosocial mechanisms, making simple stepwise analgesic escalation insufficient for many patients. Observations: The emerging evidence supports a multidimensional strategy for treating CP pain. In some patients, pain is driven mainly by ductal obstruction, stones, strictures, inflammatory head masses, or other structural complications that may respond to endoscopic or surgical decompression. On the other hand, pain may persist because of pancreatic neuroplasticity, peripheral nerve injury, central sensitization, widespread hyperalgesia, and psychological distress. Newer tools such as the Comprehensive Pain Assessment Tool Short Form, electronic body mapping, and pancreatic quantitative sensory testing may help identify clinically relevant pain phenotypes beyond imaging alone. Although pharmacologic options remain limited, medications can provide relief in appropriately selected patients. Pregabalin has the strongest direct evidence among neuromodulators with favorable results. However, opioids remain widely prescribed even though they worsen dependency, opioid-induced hyperalgesia, and treatment resistance when used without reassessment of the dominant pain mechanism. Nonpharmacological modalities are an essential component. These include alcohol and smoking cessation, nutritional and endocrine optimization, and cognitive behavioral therapy. Endoscopic and surgical therapies are most effective when pain is anatomy-driven, while neuromodulation and other emerging interventions remain investigational but may be a promising option for nociplastic pain. Conclusions and relevance: Pain in CP should be approached as a dynamic biopsychosocial process by a multidisciplinary team. In addition to pain intensity, outcome measures should capture pain interference, function, quality of life, and opioid burden. Correctly identifying the pain phenotype and matching patients with the appropriate mechanism-based therapies and structural interventions will maximize treatment success and reduce prolonged opioid escalation and repeated low-yield interventions.
- 26 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 548-556.e2
Endoscopic Submucosal Dissection for Locally Recurrent Gastric Neoplasia Following Endoscopic Resection: A Systematic Review and Meta-Analysis
- 26 March 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (4) , 548-556.e2
Endoscopic Submucosal Dissection for Locally Recurrent Gastric Neoplasia Following Endoscopic Resection: A Systematic Review and Meta-Analysis
- Open Access
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1795419
Targeted therapeutics for pancreatitis
Importance: Acute pancreatitis (AP) can result in significant morbidity and mortality. Its complications include persistent organ failure, necrosis, and death. Recurrent episodes of AP may also result in chronic pancreatitis (CP), a fibroinflammatory condition characterized by chronic pain and endocrine and exocrine failure. Despite improved supportive care, approved disease-modifying targeted therapies for AP or CP are lacking. Observations: Mechanistic studies identify early pathways within acinar and ductal cells that lead to injury, providing potential therapeutic targets before necrosis and other complications develop. Sustained cytosolic calcium elevation drives premature enzyme activation and mitochondrial failure, maintained by store-operated calcium entry through Orai1. Calcium overload promotes increased mitochondrial permeability, ATP depletion, and necrotic cell death. Potential early interventions include Orai1 inhibition (CM4620/Auxora with early-phase human safety data and phase 2b signals), mitochondrial pore inhibition (NIM811) and other mitochondrial protectants. When systemic inflammation escalates, preclinical containment targets include NLRP3 inflammasome signaling, neutrophil extracellular traps, damage-associated molecular pattern signaling (including HMGB1), and upstream cytokine shedding via ADAM17/TACE. Pragmatic strategies under study, such as early high-energy feeding, test whether modifiable supportive inputs can shift early severity trajectories. In chronic pancreatitis, long-term disease modification centers on targeting pancreatic stellate cells, which are critical drivers of fibrosis. Furthermore, the highly morbid chronic pain of CP can be modified through treatment of neuroimmune pain sensitization. The emerging clinical pipeline includes repurposed anti-fibrotic or immunomodulatory agents (pirfenidone, paricalcitol, tocilizumab, proglumide), genotype-matched therapy (CFTR modulation in selected populations), and cell-based approaches. Conclusion and Relevance: The current targeted therapeutic landscape in pancreatitis is promising, but difficulties lie in trial enrichment as the timing of drug administration is critically dependent on the timeline of disease. Therefore, progress will depend on matching treatment timing to target biology, identifying patients using practical early severity and inflammatory features, and using endpoints that reflect disease modification (organ failure, necrosis, recurrence, fibrosis progression, pancreatic function, and pain trajectories). Trial designs matching these therapeutics to their target biology will help understand the real clinical value of mechanism-based regimens across the AP–RAP–CP continuum.
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 17, 1795419
Open AccessTargeted therapeutics for pancreatitis
Importance: Acute pancreatitis (AP) can result in significant morbidity and mortality. Its complications include persistent organ failure, necrosis, and death. Recurrent episodes of AP may also result in chronic pancreatitis (CP), a fibroinflammatory condition characterized by chronic pain and endocrine and exocrine failure. Despite improved supportive care, approved disease-modifying targeted therapies for AP or CP are lacking. Observations: Mechanistic studies identify early pathways within acinar and ductal cells that lead to injury, providing potential therapeutic targets before necrosis and other complications develop. Sustained cytosolic calcium elevation drives premature enzyme activation and mitochondrial failure, maintained by store-operated calcium entry through Orai1. Calcium overload promotes increased mitochondrial permeability, ATP depletion, and necrotic cell death. Potential early interventions include Orai1 inhibition (CM4620/Auxora with early-phase human safety data and phase 2b signals), mitochondrial pore inhibition (NIM811) and other mitochondrial protectants. When systemic inflammation escalates, preclinical containment targets include NLRP3 inflammasome signaling, neutrophil extracellular traps, damage-associated molecular pattern signaling (including HMGB1), and upstream cytokine shedding via ADAM17/TACE. Pragmatic strategies under study, such as early high-energy feeding, test whether modifiable supportive inputs can shift early severity trajectories. In chronic pancreatitis, long-term disease modification centers on targeting pancreatic stellate cells, which are critical drivers of fibrosis. Furthermore, the highly morbid chronic pain of CP can be modified through treatment of neuroimmune pain sensitization. The emerging clinical pipeline includes repurposed anti-fibrotic or immunomodulatory agents (pirfenidone, paricalcitol, tocilizumab, proglumide), genotype-matched therapy (CFTR modulation in selected populations), and cell-based approaches. Conclusion and Relevance: The current targeted therapeutic landscape in pancreatitis is promising, but difficulties lie in trial enrichment as the timing of drug administration is critically dependent on the timeline of disease. Therefore, progress will depend on matching treatment timing to target biology, identifying patients using practical early severity and inflammatory features, and using endpoints that reflect disease modification (organ failure, necrosis, recurrence, fibrosis progression, pancreatic function, and pain trajectories). Trial designs matching these therapeutics to their target biology will help understand the real clinical value of mechanism-based regimens across the AP–RAP–CP continuum.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Two Ducts, One Drug—Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign
Immune checkpoint inhibitors (ICIs) can rarely result in ICI-induced pancreatic injury (ICI-PI). Its clinical and radiologic presentation is heterogenous, ranging from asymptomatic radiological signs to severe pancreatitis. Management is mainly with supportive measures and drug discontinuation. In this study, we present an unusual case of ICI-PI, secondary to pembrolizumab, resulting in dilation of both pancreatic and common bile ducts, displaying a “double-duct” sign on imaging. This radiologic sign, commonly associated with malignancy, has not been previously reported with ICI-PI. Endoscopic retrograde cholangiopancreatography with plastic stent placement resulted in quick improvement, highlighting the potential role of endotherapy in treatment of ICI-PI.
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11)
Open AccessTwo Ducts, One Drug—Pembrolizumab-Induced Pancreatic Injury Manifesting as Double-Duct Sign
Immune checkpoint inhibitors (ICIs) can rarely result in ICI-induced pancreatic injury (ICI-PI). Its clinical and radiologic presentation is heterogenous, ranging from asymptomatic radiological signs to severe pancreatitis. Management is mainly with supportive measures and drug discontinuation. In this study, we present an unusual case of ICI-PI, secondary to pembrolizumab, resulting in dilation of both pancreatic and common bile ducts, displaying a “double-duct” sign on imaging. This radiologic sign, commonly associated with malignancy, has not been previously reported with ICI-PI. Endoscopic retrograde cholangiopancreatography with plastic stent placement resulted in quick improvement, highlighting the potential role of endotherapy in treatment of ICI-PI.
- Open Access
- 15 August 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (3) , 53
Magnetically Controlled Capsule Endoscopy for Esophageal Varices: Systematic Review and Meta-Analysis
Background: Magnetically controlled capsule endoscopy (MCCE) has shown promise in upper gastrointestinal evaluation and is a potentially less invasive alternative to esophagogastroduodenoscopy (EGD). We performed a systematic review and meta-analysis aiming to measure its diagnostic performance compared to EGD for esophageal varices. Methods: Our protocol was registered on PROSPERO (CRD420251081967). A systematic search of multiple databases was conducted through July 2025 for studies assessing the diagnostic performance of MCCE compared to EGD for EV. The primary outcomes were sensitivity and specificity. Secondary outcomes included the area under the curve (AUC), likelihood ratios, diagnostic odds ratio, and safety. Pooled effect estimates were calculated using a random effects model and expressed as proportions with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic. Results: Five prospective studies with 795 patients (68.8% male, mean age of 55.1) were included. The pooled sensitivity and specificity were 87.1% (95% CI: 68.5–95.4) and 95.2% (95% CI: 88.4–98.1), respectively, with an AUC of 0.97. Following subgroup analysis of cirrhotic patients, pooled sensitivity and specificity were 96.0% (95% CI: 93.6–97.5; I2 = 43%) and 95.2% (95% CI: 84.2–98.6; I2 = 88.4%), respectively. Furthermore, MCCE use with detachable strings increased sensitivity to 96% (95% CI: 93.7–97.5; I2 = 0%) and specificity to 96.3% (95% CI: 87.2–99.0; I2 = 76.8%). Only four adverse events occurred across the five studies. Conclusions: Our meta-analysis demonstrated the high sensitivity, specificity, and diagnostic accuracy of MCCE, along with a favorable safety profile. Further large-scale trials are needed to validate our findings.
- 15 August 2025
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 7 (3) , 53
Open AccessMagnetically Controlled Capsule Endoscopy for Esophageal Varices: Systematic Review and Meta-Analysis
Background: Magnetically controlled capsule endoscopy (MCCE) has shown promise in upper gastrointestinal evaluation and is a potentially less invasive alternative to esophagogastroduodenoscopy (EGD). We performed a systematic review and meta-analysis aiming to measure its diagnostic performance compared to EGD for esophageal varices. Methods: Our protocol was registered on PROSPERO (CRD420251081967). A systematic search of multiple databases was conducted through July 2025 for studies assessing the diagnostic performance of MCCE compared to EGD for EV. The primary outcomes were sensitivity and specificity. Secondary outcomes included the area under the curve (AUC), likelihood ratios, diagnostic odds ratio, and safety. Pooled effect estimates were calculated using a random effects model and expressed as proportions with 95% confidence intervals (CI). Heterogeneity was assessed using the I2 statistic. Results: Five prospective studies with 795 patients (68.8% male, mean age of 55.1) were included. The pooled sensitivity and specificity were 87.1% (95% CI: 68.5–95.4) and 95.2% (95% CI: 88.4–98.1), respectively, with an AUC of 0.97. Following subgroup analysis of cirrhotic patients, pooled sensitivity and specificity were 96.0% (95% CI: 93.6–97.5; I2 = 43%) and 95.2% (95% CI: 84.2–98.6; I2 = 88.4%), respectively. Furthermore, MCCE use with detachable strings increased sensitivity to 96% (95% CI: 93.7–97.5; I2 = 0%) and specificity to 96.3% (95% CI: 87.2–99.0; I2 = 76.8%). Only four adverse events occurred across the five studies. Conclusions: Our meta-analysis demonstrated the high sensitivity, specificity, and diagnostic accuracy of MCCE, along with a favorable safety profile. Further large-scale trials are needed to validate our findings.